NCT05546580 - Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory

Interventions

DRUG

Iadademstat

iadademstat oral solution

DRUG

Gilteritinib Oral Tablet

120 mg Gilteritinib

Trial Locations (13)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, New York

26506

RECRUITING

West Virginia University, Morgantown

27705

RECRUITING

Duke University Medical Center, Durham

33136

RECRUITING

Sylvester Comprehensive Cancer Center, Miami

33176

RECRUITING

Miami Cancer Institute, Miami

37203

RECRUITING

Sarah Cannon Research Institute, LLC, Nashville

53226

RECRUITING

Froedtert Hospital & The Medical College of Wisconsin, Milwaukee

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

97239

RECRUITING

Oregon Health & Science University, Portland

85724-5024

RECRUITING

The University of Arizona Cancer Center - North Campus, Tucson

21287-0013

RECRUITING

The John Hopkins University School of Medicine, Baltimore

02114

RECRUITING

Massachusetts General Hospital (MGH), Boston

08854

RECRUITING

Rutgers, The State University, Piscataway